Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pneumonia multivalent conjugate vaccine and preparation method thereof

A technology combining vaccines and pneumococcal polysaccharides, applied in the biological field, can solve the problems of inability to induce immune memory effects, inability to effectively activate the complement system, and low-affinity antibodies.

Active Publication Date: 2017-08-04
BRAVOVAX +1
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But this kind of polysaccharide vaccine has the following problems: (1) in young animals or infants, only weak immune response can be produced, or even no immune response, and the immune response will increase with age; (2) produce low-affinity antibodies (3) only produce short-lived immune response, do not have immune memory and immune enhancement effect during repeated vaccination; (4) easy to produce immune tolerance; (5) common adjuvant is not easy to play the role of immune enhancement to this antigen Effect, the 23-valent polysaccharide vaccine has a protection rate of 50-70% for invasive pulmonary chain infection, and can only be used for vaccination of people over 2 years old, while the peak age of onset of pneumonia is 6-12 months old; (6) has Polysaccharides with repeating structures are T cell-independent type 2 immunogens. Without the participation of T cells, they cannot induce immune memory effects, and the antibodies that stimulate the body are mainly IgM and IgG2, which cannot effectively activate the complement system
[0021] However, the above-mentioned traditional polysaccharide-protein binding technology has the following disadvantages: (1) The polysaccharide-AH derivative will continue to react with the polysaccharide activated by cyanogen bromide to form a self-polymer of the polysaccharide, which reduces the polysaccharide-protein binding efficiency; (2) EDAC mediates the combination of ADH-derived polysaccharides and carrier proteins, and at the same time, it is easy to cause self-crosslinking of polysaccharides and carrier proteins, thereby reducing the binding efficiency of polysaccharides and proteins; (3) polysaccharides and carrier proteins are large organisms The molecule is connected by ADH with only 6 carbon atoms in the middle. The structure of polysaccharides and proteins is bound to influence each other, making some important epitopes of polysaccharides easily shielded by proteins, thereby reducing the immunogenicity of polysaccharides
[0033] There are also reports that nano-microspheres can be used as carrier proteins and adjuvants for DNA vaccines, but there is no report on their application in prophylactic polysaccharide and / or protein vaccines

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pneumonia multivalent conjugate vaccine and preparation method thereof
  • Pneumonia multivalent conjugate vaccine and preparation method thereof
  • Pneumonia multivalent conjugate vaccine and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0099] 1. Preparation of magnetic nanospheres

[0100] 1. Take 2.24g FeSO 4 -7H 2 O and 3.24 g FeCl 3 -6H 2 O dissolved in 10 mL and 15 mL of dddH 2 In O, mix well after dissolving, add 100mL of dddH filtered to remove oxygen 2 O;

[0101] 2. In N 2 Stir for 5 minutes under the protection of the solution, add 50mL1mol / L NaOH solution at one time, adjust the pH of the solution to 9-10, increase the stirring speed to 200-250r / min, and continue stirring for 30min;

[0102] 3. Transfer the reaction vessel to a 65-70°C water bath and continue to 2 Stirring and aging under the protection of 30min;

[0103] 4. After the reaction, set the volume to 100mL, and observe the synthesis of magnetic particles under a microscope;

[0104] 5. Dissolve 400mgPLGA in 10mLEA solvent as the oil phase (O), add 3mL of the above magnetic particle solution as the inner water phase (W 1 ), using an ultrasonic cell breaker (120W, 60s) to carry out colostrum in an ice-water bath to prepare colos...

Embodiment 2

[0150] The difference between this example and Example 1 is that the carrier protein of the pneumonia multivalent conjugate vaccine is tetanus toxoid carrier protein and PspA.

[0151] The compositional analysis results of the prepared pneumonia multivalent conjugate vaccine are consistent with the results obtained in Example 1 within the theoretical error range.

Embodiment 3

[0153] The difference between this example and Example 1 is that the carrier protein of the pneumonia multivalent conjugate vaccine is a rotavirus carrier protein and a tetanus toxoid carrier protein.

[0154] The compositional analysis results of the prepared pneumonia multivalent conjugate vaccine are consistent with the results obtained in Example 1 within the theoretical error range.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
particle diameteraaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention discloses a pneumonia multivalent conjugate vaccine. The conjugate vaccine is formed by multivalent pneumococcus polysaccharide and two or more than two carrier proteins by virtue of a connecting body, wherein the connecting body is magnetic nanospheres. A preparation method of the pneumonia multivalent conjugate vaccine comprises that the multivalent pneumococcus polysaccharide and two or more than two carrier proteins are respectively coupled with the nanospheres. The pneumonia multivalent conjugate vaccine provided by the invention is simple in preparation technology, the multivalent conjugate vaccine adopting the nanospheres as connection substances can enhance mouse Th1 type immune response as well as immune persistent effect, specificity and affinity of a polysaccharide specific antibody, and a mouse can be induced to produce a rotavirus antibody; and the pneumonia multivalent conjugate vaccine has preventive effects of two vaccines, so that the pneumonia multivalent conjugate vaccine provided by the invention has a broad application prospect.

Description

technical field [0001] The invention relates to a vaccine, in particular to a pneumonia multivalent combination vaccine and a preparation method thereof, belonging to the field of biotechnology. Background technique [0002] 1. The harm of microorganisms to the human body and countermeasures [0003] Microorganisms usually refer to those biological groups whose individual volume diameter is generally less than 1mm. They have a simple structure, most of which are single cells, and some do not even have a cell structure. To clarify their morphology and structure; Among them, pathogenic microorganisms refer to pathogenic microorganisms that can cause diseases of humans, animals and plants. The pathogenicity of a pathogen depends on its ability to invade the host and reproduce in vivo and resist host resistance without being eliminated by it. The pathogenicity of microorganisms has species characteristics, and the degree of pathogenicity is called virulence. The establishment...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/39A61K39/385A61K39/295A61K39/116A61K39/09A61P31/04A61P31/14
CPCA61K39/09A61K39/12A61K39/385A61K39/39A61K2039/55516A61K2039/57A61K2039/6075A61K2039/627A61K2039/70C12N2720/12334
Inventor 艾智武刘昊智史晋吴克
Owner BRAVOVAX
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com